One Year Survival of Extrahepatic Cholangiocarcinoma Patients Who Did Not Undergo Curative Resection and Paliative Chemotherapy and Its Associated Factors

Authors

  • Pieter Saragih Department of Internal Medicine, Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia
  • Dadang Makmun Division of Gastroenterology, Pancreatobiliary and Digestive Endoscopy, Department of Internal Medicine, Faculty of Medicine Universitas Indonesia - Cipto Mangunkusumo Hospital, Jakarta, Indonesia
  • Juferdy Kurniawan Division of Hepatobiliary, Department of Internal Medicine, Faculty of Medicine Universitas Indonesia - Cipto Mangunkusumo Hospital, Jakarta, Indonesia
  • Ikhwan Rinaldi Division of Hematology and Medical Oncology, Department of Internal Medicine, Faculty of Medicine Universitas Indonesia - Cipto Mangunkusumo Hospital, Jakarta, Indonesia

Keywords:

survival, extrahepatic cholangiocarcinoma, curative resection, paliative chemotherapy, mortality-related factors

Abstract

Background: Extrahepatic cholangiocarcinoma is rare but fatal. Patients who come are usually already in the advanced stage that can not undergo curative resection and chemotherapy also seems to be very rarely done. The survival rate and its associated factors in Indonesia are unknown. This study aimed to identify 1-year survival of patients with extrahepatic cholangiocarcinoma without curative resection and palliative chemotherapy and its associated factors. Methods: This is a cross-sectional study using medical records of extrahepatic cholangiocarcinoma (perihilar and distal) inpatient and outpatient patients at Cipto Mangunkusumo Hospital, Jakarta from January 2015 to March 2020, reviewed retrospectively. The following factors were analyzed in terms of mortality: metastasis, sepsis, hypoalbuminemia, serum bilirubin level, serum CA 19-9 level, billiary drainage, neutrophyl lympocyte ratio (NLR) and comorbid factors. Results: 115 out of 144 patients were enrolled in this study with male proportion of 50.4%, and proportion of patients aged 65 years or above was 71.3%. 1 year survival rate was 10 % and median survival was 3 months (CI 95% 2.388-3.612)Multivariate analysis showed that only sepsis, unsuccessful or no prior biliary drainage and total bilirubin >19.8 mg/dl were independent predictors of mortality. Conclusion: 1 year survival of extrahepatic cholangiocarcinoma without curative resection and paliative chemotherapy was 10 %.Sepsis, unsuccessful or no prior bilirary drainage, and total biirubin >19.8 mg/dl  are factors significantly associated with shortened survival in malignant obstructive jaundice patients.

References

Patel T. Cholangiocarcinoma: controversies and challenges. Nat Rev Gastroenterol Hepatol. 2011;8(4):189-200.

Park J, Kim MH, Kim KP, et al. Natural history and prognostic factors of advanced cholangiocarcinoma without surgery, chemotherapy, or radiotherapy: A large-scale observational study. Gut Liver. 2009;3(4):298-305.

Kurniawan J HI, Gani RA, Simadibrata M. Mortality-related factors in patients with malignant obstructive jaundice. Acta Med Indones. 2016;48(4):282-7.

Fernandez-Ruiz M, Guerra-Vales JM, Colina-Ruizdelgado F. Comorbidity negatively influences prognosis in patients with extrahepatic cholangiocarcinoma. World J Gastroenterol. 2009;15(42):5279-86.

Aktas G KT, Balkan A, Metin T, Gulsen MT, Abali H. Prognostic factors in patients with advanced extrahepatic cholangiocarcinoma. Medicine (Baltimore). 2019;98:e14556.

Harder J, Kummer O, Olschewski M, Otto F, Blum HE, Opitz O. Prognostic relevance of carbohydrate antigen 19-9 levels in patients with advanced biliary tract cancer. Cancer Epidemiol Biomarkers Prev. 2007;16(10):2097-100.

Wu CE, Chou WC, Hsieh CH, et al. Prognostic and predictive factors for Taiwanese patients with advanced biliary tract cancer undergoing frontline chemotherapy with gemcitabine and cisplatin: a real-world experience. BMC Cancer. 2020;20(1):422.

Wang Y, Pang Q, Jin H, et al. Albumin-bilirubin grade as a novel predictor of survival in advanced extrahepatic cholangiocarcinoma. Gastroenterol Res Pract. 2018:8902146.

Khan SA DB, Goldin RD, Heaton N, et al. Guidelines for the diagnosis and treatment of cholangiocarcinoma: an update. Gut. 2012;61:1657-69.

Yusoff AR, Razak MM, Yoong BK, Vijeyasingam R, Siti ZM. Survival analysis of cholangiocarcinoma: a 10-year experience in Malaysia. World J Gastroenterol. 2012;18(5):458-65.

Benavides MAA, J Gallego, Go´mez MA, et al. Biliary tract cancers: SEOM guidelines. Clin Trans Oncol. 2015;17:982-7.

Weber A LS, Scnhneider J, Stangl M, et al. Long term outcome and prognostic factors of patients with hilar cholangiocarcinoma. World J Gastroenterol. 2007;13(9):1422-6.

Yang LC SH, Huang JW, Lee KT. Biliary stenting for unresectable cholangiocarcinoma: A population based study of long term outcomes and hospital costs in Taiwan. Kaohsiung J Med Sci. 2015;31(7):370-6.

Qiu YD BJ, Xu FG, Ding YT. Effect of perioperative biliary drainage on malignant obstructive jaundice : a metaanalysis. World J Gastroenterol. 2011;17(3):391-6.

Pavlidis ET PT. Pathophysiological consequences of obstructive jaundice and perioperative management. Hepatobiliary Pancreat Dis Int. 2018;17(1):17-21.

Rerknimitr R, Fogel EL, Kalayci C, Esber E, Lehman GA, Sherman S. Microbiology of bile in patients with cholangitis or cholestasis with and without plastic biliary endoprosthesis. Gastrointest Endosc. 2002;56(6):885-9.

Li L, Zhu C, Huang H. Clinical epidemiology and outcomes of biliary tract infections caused by Klebsiella pneumoniae. Ann Transl Med. 2019;7(14):304.

Gaspersz MP, Buettner S, van Vugt JLA, et al. Conditional survival in patients with unresectable perihilar cholangiocarcinoma. HPB (Oxford). 2017;19(11):966-71.

Zhang GY, Li WT, Peng WJ, Li GD, He XH, Xu LC. Clinical outcomes and prediction of survival following percutaneous biliary drainage for malignant obstructive jaundice. Oncol Lett. 2014;7(4):1185-90.

Brountzos EN, Ptochis N, Panagiotou I, Malagari K, Tzavara C, Kelekis D. A survival analysis of patients with malignant biliary strictures treated by percutaneous metallic stenting. Cardiovasc Intervent Radiol. 2007;30(1):66-73.

Downloads

Published

2022-04-08

How to Cite

Saragih, P., Makmun, D., Kurniawan, J., & Rinaldi, I. (2022). One Year Survival of Extrahepatic Cholangiocarcinoma Patients Who Did Not Undergo Curative Resection and Paliative Chemotherapy and Its Associated Factors. Acta Medica Indonesiana, 54(1), 35. Retrieved from https://actamedindones.org/index.php/ijim/article/view/1929

Issue

Vol. 54 No. 1 (2022): Acta Medica Indonesiana

Section

ORIGINAL ARTICLE

License

Copyright

The authors who publish in this journal agree to the following requirements:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a  Creative Commons Attribution 4.0 International License (CC BY 4.0) that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
  2. Authors can enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) before and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work. (See The Effect of Open Access)

Privacy Statement

The names and email addresses entered in this journal site will be used exclusively for the stated purposes of this journal and will not be made available for any other purpose or to any other party.